M&A | Partnerships

Seikagaku and Eisai will co-develop and market knee osteoarthritis treatment SI-613 in China.

Acumed entered into an agreement to distribute Vivorte's orthobiologic portfolio on an exclusive basis.

Biologics4Life completed an exclusive licensing agreement to secure rights to initial technologies for bone tissue regeneration.

Anika Therapeutics signed agreements to acquire Parcus Medical and Arthrosurface within 1Q20.

Advanced Medical Solutions acquired Biomatlante, developer, and manufacturer of orthobiologic products with application in joint reconstruction, spine, trauma, and sports medicine procedures.

Molecular Matrix will enter into a strategic alliance with Philosys Healthcare to expand availability of bone graft substitute technology in the Asian market.

Bioventus entered into a U.S. contract with UnitedHealthcare whereby UH's commercial plan members will have access to DUROLANE and GELSYN-3 to treat knee osteoarthritis pain. 

Ortho Regenerative Technologies entered into an agreement to evaluate a commercial product from an unnamed orthopedic company partner for use with Ortho's Ortho-R biopolymer matrix. 

Onkos Surgical will market Bone Solutions' OsteoCrete® magnesium-based bone void filler under the GenVie brand through a private label agreement.

WishBone Medical entered into a private label distribution agreement with Bone Solutions for worldwide rights to sell OsteoCrete® bone void filler in pediatric applications.